Alpine Bio Raises $75.0M Series B Funding

Alpine Bio has raised $75.0 million in a recent funding round, securing significant investment capital from investors.

This funding will support the company's mission to design ingredients with unprecedented purity and functionality through both advanced protein isolation and molecular farming.

Alpine Bio focuses on solving the purity paradox, aiming to scale premium specifications at commodity economics within the ingredient market.

The company's platform currently offers three breakthrough ingredients.

These include FSPI, a fractionated soy protein isolate with up to 99% purity, which provides whey-like solubility and neutral flavor without requiring gums or stabilizers.

Alpine Bio also produces pharmaceutical-purity Lactoferrin from plant production, offering full bioactive function for immunity and iron absorption with 3.

5x higher iron saturation than bovine sources.

Furthermore, it develops Casein, designed to deliver complete dairy functionality grown directly in plants, matching the stretch, melt, and nutrition of milk casein.

This substantial capital infusion is expected to accelerate Alpine Bio's strategic growth initiatives.

The funds will be allocated towards expanding its research and development efforts, scaling its production capabilities, and advancing the commercialization of its innovative ingredient portfolio.

The company collaborates with formulators and brands to take custom ingredient designs from genetic blueprint to commercial scale.

The successful completion of this funding round highlights investor confidence in Alpine Bio's proprietary technology and its potential to innovate within the ingredient sector.

This investment positions Alpine Bio to further disrupt the market by providing sustainable, high-performance alternatives for various industries, supporting its ongoing efforts to bring more breakthrough ingredients to market.